FindTrial
Sign In

EpiReg India

Prospective longitudinal observational study to assess disease burden, risk factors, and management approaches in Epilepsy.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/10/058462
Enrollment
6500
Registered
2023-10-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G40- Epilepsy and recurrent seizures

Interventions

None listed

Sponsors

Eris Lifesciences Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Data of the randomly selected Epilepsy patients.

Exclusion criteria

Exclusion criteria: Incompletely filled case record forms will excluded from analysis.

Design outcomes

Primary

MeasureTime frame
To understand the long-term course and treatment outcomes in patients with epilepsy in the Indian population.Timepoint: After every six months for three years—

Secondary

MeasureTime frame
To evaluate crucial aspects of epilepsy like symptom variability, long-term effects of AEDs, Quality of life, sleep, pregnancy, medical and psychiatric comorbidity, and treatment adherence and factors affecting remission. To evaluate quality of life, severity of depression and anxiety during study.Timepoint: After every six months for three years—

Countries

India

Contacts

Public ContactDr Suresh Sathe

Eris Lifesciences Ltd.

suresh.sathe@erislifesciences.com917930451111

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026